Verona Pharma PLC Board Change (2724B)
April 03 2017 - 2:01AM
UK Regulatory
TIDMVRP
RNS Number : 2724B
Verona Pharma PLC
03 April 2017
FOR RNS RELEASE:
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
Board Change
3 April 2017, London - Verona Pharma plc (AIM: VRP.L) ("Verona
Pharma" or the "Company"), a clinical-stage biopharmaceutical
company focused on developing and commercialising innovative
therapeutics for the treatment of respiratory diseases with
significant unmet medical needs, announced today that Patrick
Humphrey D.Sc, OBE, has decided to retire from the Board as a
Non-Executive Director, to take effect on 15 April 2017. Patrick
joined the Verona Pharma Board in 2009, and there are no plans to
replace him. The role of Dr. Humphrey on the Nominations and
Corporate Governance Committee, will be filled by Dr. Anders
Ullman, currently a Non-Executive Director of the Company.
David Ebsworth, Chairman of the Board of Verona Pharma,
commented:
"We would like to thank Pat for his many important contributions
to the Company's R&D strategy, his long service and his
dedication to the Company. He has been a valuable member of the
Board since joining in 2009, and will continue to contribute to the
Company's research and development activities in an advisory
capacity."
-ENDS-
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283
4200
Jan-Anders Karlsson, Chief Executive info@veronapharma.com
Officer
N+1 Singer (Nominated Adviser Tel: +44 (0)20 7496
and UK Broker) 3000
Aubrey Powell / James White
FTI Consulting (UK Media and Tel: +44 (0)20 3727
Investor enquiries) 1000
Simon Conway / Stephanie Cuthbert veronapharma@fticonsulting.com
/
Natalie Garland-Collins
ICR, Inc. (US Media and Investor
enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company
focused on developing and commercialising innovative therapeutics
for the treatment of respiratory diseases with significant unmet
medical needs. Verona Pharma's product candidate, RPL554, is a
first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 that acts as both a bronchodilator and an
anti--inflammatory agent in a single compound. In clinical trials,
treatment with RPL554 has been observed to result in statistically
significant improvements in lung function as compared to placebo
and has shown clinically meaningful and statistically significant
improvements in lung function when added to two commonly used
bronchodilators as compared to either bronchodilator administered
as a single agent. RPL554 has also shown anti-inflammatory effects
and been well tolerated in clinical trials. Verona Pharma is
developing RPL554 for the treatment of chronic obstructive
pulmonary disease (COPD), cystic fibrosis, and potentially
asthma.
Forward Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including without limitation statements regarding the
effective date of Dr. Humphrey's retirement and our corporate
governance plans.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from our
expectations expressed or implied by the forward-looking
statements.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this
press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEASLAEEKXEFF
(END) Dow Jones Newswires
April 03, 2017 02:01 ET (06:01 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024